# A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

> **NCT02533453** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 110 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Bydureon

## Key facts

- **NCT ID:** NCT02533453
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-28
- **Primary completion:** 2016-12-07
- **Final completion:** 2016-12-07
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533453, "A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02533453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*